Futu News on June 27th, this Monday. $RAINMED-B (02297.HK)$Announcement issued, will conduct a public offering from June 27th to June 30th, the company intends to issue 23.348 million shares, with 2.336 million shares for public offering and 21.012 million shares for international offering, at an issue price of HK$4.28-6.24 per share, in lots of 1000 shares, expected to be listed on July 8th.
The prospectus shows that Runmaide-B is a Chinese medical instruments company established in 2014. Its core products caFFR system and caIMR system are mainly used to assess the severity of myocardial ischemia caused by coronary stenosis and microvascular functional disorders.
Runmaide-B is one of the first companies to commercially launch FFR systems based on coronary angiography in China. Its caFFR system has become a leading FFR measurement product domestically, with an accuracy rate of 95.7%, the highest among domestic FFR measurement products.
The company is currently developing its caIMR system, which is the only minimally invasive IMR measurement product in the world that has completed confirmatory clinical trials and is expected to become the world's first minimally invasive IMR system to be approved for commercialization.
The company's goal is to leverage the caFFR system and caIMR system as core diagnostic modules to produce industry-leading vascular interventional surgery siasun robot&automation. This is an all-in-one hybrid procedure that diagnoses and treats by connecting and integrating all clinical application areas, including percutaneous coronary...